Redcare Pharmacy Aktie: Sharp Sell-Off as 2026 Outlook Signals Growth Slowdown
FRANKFURT, 04 March 2026 — Investors in Redcare Pharmacy N.V. (formerly Shop Apotheke Europe) are facing a turbulent trading session today. Following the release of the final financial results for 2025 and a cautious outlook for the current fiscal year, the stock has entered a significant downward spiral, reaching its lowest valuation since early 2023. While the company celebrated record revenues in the previous year, the market is reacting sharply to a projected “growth dent” for 2026.
Market Reaction: Shares Plunge on Wednesday
As of midday on 04 March 2026, the Redcare Pharmacy share (ETR: RDC) has experienced a dramatic decline. The stock fell by approximately 8.72%, trading around the €54.83 mark. This acceleration of the downward trend has effectively doubled the year-to-date losses for 2026. Analysts note that the sell-off is driven by disappointment over the company’s guidance, which suggests a transition from hyper-growth to a more moderate expansion phase.
Key Financial Indicators (FY 2025 vs. 2026 Forecast)
The following table outlines the core financial performance of Redcare Pharmacy based on the latest corporate data and the newly released 2026 guidance:
| Metric | FY 2025 (Actual) | FY 2026 (Forecast) |
|---|---|---|
| Group Revenue | €2.9 Billion | +13% to 15% Growth |
| Rx (Prescription) Revenue | > €1 Billion | Moderate Growth Expected |
| Adj. EBITDA Growth | +72% (Year-on-Year) | Focus on Margin Stability |
| Revenue Growth Rate | 24% | 13% – 15% |
The 2026 Outlook: A “Growth Dent” or Strategic Pivot?
The primary catalyst for the current share price weakness is the management’s forecast for 2026. After achieving a 24% revenue increase in 2025, the company now expects growth to cool down to a range of 13% to 15%.
Challenges in the Non-Rx Segment
While the prescription drug (Rx) business in Germany remains a strong pillar—surpassing the €1 billion mark in 2025—the market remains skeptical regarding the profitability of the non-prescription (Non-Rx) segment. Uncertainty in consumer spending and rising operational costs have led investors to price in risks concerning the long-term EBITDA margin.
Analyst Divergence: UBS vs. Barclays
Financial institutions remain divided on the stock’s future trajectory.
- UBS: Has maintained a “Neutral” rating with a price target of €74.00, citing the transition to more moderate growth as a reason for caution.
- Barclays: Remains significantly more optimistic, maintaining an “Overweight” rating with a price target of €110.00. This represents a potential upside of over 120% from current levels, based on the belief that the market is overreacting to short-term guidance.
Company Background and Structure
Redcare Pharmacy N.V., headquartered in Sevenum, Netherlands, is a leading online pharmacy group in Europe. Historically emerging from the structures of the German mail-order pharmacy DocMorris, the company rebranded from Shop Apotheke Europe in 2023 to reflect its broader healthcare ambitions. The group operates across several European markets, focusing on the digitisation of the traditional pharmacy model.
Frequently Asked Questions (FAQ)
Why is the Redcare Pharmacy share falling today?
The share price is dropping primarily due to the 2026 revenue guidance, which forecasts a growth slowdown to 13-15%, compared to the 24% growth achieved in 2025. Investors are also concerned about the sustainability of profit margins in the non-prescription sector.
What was the revenue of Redcare Pharmacy in 2025?
In the fiscal year 2025, Redcare Pharmacy achieved a total group revenue of €2.9 billion, with the prescription drug (Rx) segment contributing over €1 billion for the first time.
Where is Redcare Pharmacy headquartered?
The company is a public limited company (N.V.) based in Sevenum, the Netherlands, though it has deep historical roots in the German pharmacy market, specifically starting from a local pharmacy in Cologne over 20 years ago.
What is the current analyst consensus?
Opinions are split. While some banks like UBS remain neutral due to the growth outlook, others like Barclays see the current price drop as a massive buying opportunity, setting price targets well above €100.